RBM to Develop, Sell Schizophrenia Biomarker Test with Psynova Neurotech | GenomeWeb
NEW YORK (GenomeWeb News) – Rules-Based Medicine said today it will work with start-up drug firm Psynova Neurotech to develop and sell a biomarker-based blood test that could be used to help diagnose schizophrenia. 
 
The companies will work together to validate, seek regulatory approval for, and manufacture the schizophrenia test, which RBM will sell exclusively worldwide.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.